Abstract: Objective To investigate the clinical value of cervical thin-layer cytology test(TCT)and high-risk human papilloma virus(hrHPV)detection in patients with cervical cancer and cervical intraepithelial neoplasia. Methods Clinical therapentic conditions of 72 cervical cancer and cervical intraepithelial neoplasia patients were retrospectively analyzed. All patients performed TCT and hrHPV. The sensitivities and specificities of TCT and hrHPV detection were analyzed, and their coincidence rates with pathological results were analyzed. Results TCT results of 72 patients showed that 42 cases presented normal results, accounting for 58.3%(42/72), and 30 cases were abnormal, accounting for 41.7%(30/72). The rate of TCT detection that was in with pathological results of cervical intraepithelial neoplasia was 44.2%(19/43), the rate of TCT detection that was in with pathological results of cervical cancer was 72.7%(8/11). The hrHPV test results showed that 52 patients were positive, accounting for 72.2%(52/72), and 20 patients were negative, accounting for 27.8%(20/72). The rate of hrHPV detection accordance with pathological results was 86.0%(37/43)in diagnosis of cervical intraepithelial neoplasia and was 90.9%(10/11)by TCT in diagnosis of cervical cancer. The sensitivity and coincidence rate of TCT and hrHPV combined detection were 94.4% and 90.3% respectively, which were significantly higher than TCT or hrHPV detection alone. Conclusion TCT - and hrHPV combined detection can improve the detection rate of patients with cervical cancer and cervical intraepithelial neoplasia.